Drugs / Darinaparsin
Darinaparsin
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT01689220 | Sep 2012 → Jan 2014 | peripheral T-cell lymphoma, not otherwise specified | Solasia Pharma K.K. | Completed | No outcome recorded |
| Phase 1 | NCT01435863 | Sep 2011 → Apr 2015 | peripheral T-cell lymphoma, not otherwise specified | Solasia Pharma K.K. | Completed | No outcome recorded |
| Phase 1 | NCT01139346 | Jun 2010 → Apr 2012 | cancer | Alaunos Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01139359 | Jun 2010 → Jun 2011 | lymphoma | Alaunos Therapeutics | Withdrawn | No outcome recorded |
| Phase 1 | NCT00592163 | Dec 2007 → Jun 2013 | cancer, lymphoma | Alaunos Therapeutics | Unknown | No outcome recorded |
| Phase 1 | NCT00591422 | Aug 2007 → Jun 2013 | cancer of unknown primary site | Alaunos Therapeutics | Unknown | No outcome recorded |
| Phase 1 | NCT00591396 | Jul 2005 → Jul 2008 | cancer | Alaunos Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00592046 | May 2005 → Jun 2008 | acute leukemia, lymphoproliferative syndrome, myelodysplastic syndrome, myeloproliferative neoplasm +1 | Alaunos Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00509782 | May 2005 → Apr 2008 | cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00303199 | Jan 2006 → Aug 2007 | plasma cell myeloma | Alaunos Therapeutics | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02653976 | Mar 2016 → Oct 2020 | peripheral T-cell lymphoma, not otherwise specified | Solasia Pharma K.K. | Completed | No outcome recorded |
| Phase 2 | NCT00423644 | Jan 2007 → Dec 2013 | plasma cell myeloma | Alaunos Therapeutics | Unknown | No outcome recorded |
| Phase 2 | NCT00423306 | Jan 2007 → Dec 2013 | hepatocellular carcinoma | Alaunos Therapeutics | Unknown | No outcome recorded |
| Phase 2 | NCT00421213 | Dec 2006 → Apr 2012 | bone marrow neoplasm, non-Hodgkin lymphoma | Alaunos Therapeutics | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Darinaparsin | “420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest for up to six months” NCT00423644 ↗13“A phase I clinical trial of darinaparsin in patients with refractory solid tumors.” PMID 19584162 ↗ Jul 2009 “ZIO-101 (Darinaparsin)” NCT00592046 ↗ |
| Known as | Darinaparsina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3247378 ↗ |
| Known as | Darinaparsine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3247378 ↗ |
| Known as | SP-02L | “Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)” NCT02653976 ↗2“SP-02L (darinaparsin for injection)” NCT01435863 ↗ “SP-02L (darinaparsin for injection)” NCT01689220 ↗ |
| Known as | ZIO-101 | “ZIO-101 (Darinaparsin)” NCT00303199 ↗ |
| Modality | Small molecule | “new organic arsenic compound” NCT00303199 ↗ |
| Route | Intravenous | “IV zio-101 (Darinaparsin) give for 5 consecutive days” NCT00303199 ↗ |